Skip to main content

Advertisement

Table 3 Comparison of anti-osteoporotic medication treatment initiated after hip fracture and mortality risk

From: Adherence to anti-osteoporosis medication associated with lower mortality following hip fracture in older adults: a nationwide propensity score-matched cohort study

Study [Ref. no.] Country Design of included studies No. of patients Study population Follow-up durations, means (Y) AOM choice Within Time to AOM Mortality risk (95% CI)
Cree et al. (2003) [16] Canada Prospective, Observational 81 (treated) 275 (non-treated) F and M Age ≥ 65 4Y HRT, BO, calcitonin, vit-D3 Post-fx 6 M (37%) 0.25 (0.06–1.12) 1-year. 0.34 (0.17–0.70) long-term.
Lyles et al. (2007) [17] International, multicenter RCT 1065 (treated) 1062 (placebo) F and M Age ≥ 50 1.9 Y Zoledronic acid Post-op 90D 0.72 (0.56–0.93)
Cecilia et al. (2009) [18] Spain RCT 119 (treated) 120 (placebo) F and M Age ≥ 60 1Y Alendronate Post-op 2-4D 0.86 (.29–1.89)
Nurmi et al. (2009) [19] Finland Prospective, Observational 103 (treated) 118 (non-treated) F and M Age ≥ 70 (80.5%) 4Y HRT, BO, vit-D3, calcitonin, SERM, teriparatide NA 0.8–0.98
Cameron et al. (2010) [20] Australia Nested case-control 83 (treated) 366 (non-treated) F and M Age ≥ 65 5 Y BO, HRT, vit-D3, calcitonin NA 0.20 (0.07–0.55) BO use in the first 3 years Non-BO use: unremarkable
Beaupre et al. (2011) [21] Canada Prospective, Observational 101 (treated) 108 (non-treated) F and M Age ≥ 50 3Y Alendronate (68%), Risedronate (21%), Etidronate (11%). Post-fx 1Y (97%), Post-fx 1-2Y (2%), Post-fx 3Y (1%) 0.37 (0.28–0.51) per Year 0.92 (0.88–0.97) per Month
Osaki et al. (2012) [22] Japan Prospective Observational 184 (treated) 445 (non-treated) F Age ≥ 70 (93.6%) 3Y Risedronate At the time of discharge from hospital 0.29 (0.04–2.37)
Bondo et al. (2013) [23] Danish Retrospective, Observational 1086 (treated) 2147 (non-treated) F and M Age ≥ 55 3.8Y BO Post-fx 4 M 0.76 (0.68–0.85)
Brozek et al. (2016) [24] Austrian Retrospective, Observational 2166 (treated) 4332 (non-treated) F and M Age ≥ 50 4Y BO Post-fx 1Y 0.24 (0.15–0.40) 90-days 0.43 (0.36–0.52) 1-year 0.48 (0.42–0.55) 3-year
Cengiz et al. (2016) [25] Turkey RCT 56 (treated) 58 (placebo) F and M Age ≥ 65 1Y Zolendronic acid Post-op 2 W 0.41 (0.20–0.86)
Current study (2019) Taiwan Retrospective, Observational 2092 (treated) 2092 (non-treated) F and M Age ≥ 65 5Y BO, raloxifene, calcitonin, teriparatide Post-fx 6 M 0.63 (0.58–0.68) Treated 0.42 (0.31–0.52) Adherence 0.84 (0.75–0.93) Non-adherence
  1. Post-op post-operative; Post-fx post-fracture; Y year; D day; M month; W week BO Bisphosphonate; RCT randomized control trial; AOM anti-osteoporotic medication; CI confidence interval; NA not available